Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis

References

• Farrell PM The prevalence of cystic fibrosis in the European Union J Cyst Fibros 2008 7 450 453 18442953
   PubMed Web of Science ®Google Scholar
• Kerem B Rommens JM Buchanan JA Identification of the cystic fibrosis gene: genetic analysis Science 1989 245 1073 1080 2570460
   PubMed Web of Science ®Google Scholar
• Rommens JM Iannuzzi MC Kerem B Identification of the cystic fibrosis gene: chromosome walking and jumping Science 1989 245 1059 1065 2772657
   PubMed Web of Science ®Google Scholar
• Riordan JR Rommens JM Kerem B Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science 1989 245 1066 1073 2475911
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Mutation Database CFTR1 2013 Available from: http://www.genet.sickkids.on.ca/cftr/StatisticsPage.html Accessed May 16, 2013
   Google Scholar
• Cystic Fibrosis Registry Report Trust Annual Data Report 2010 12 2011 Available from: http://www.cftrust.org.uk/aboutcf/publications/cfregistryreports/UK_CF_Registry_-_Annual_Data_Report_2010.pdf Accessed May 16, 2013
   Google Scholar
• Patient Registry Annual Data Report Bethesda, MD Cystic Fibrosis Foundation 2011Available from: http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/Accessed May 16, 2013
   Google Scholar
• Cohen-Cymberknoh M Shoseyov D Kerem E Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life Am J Respir Crit Care Med 2011 183 1463 1471 21330455
   PubMed Web of Science ®Google Scholar
• Oxford University GeneMedicine CFTR Protein Structure Available from: http://www.genemedresearch.ox.ac.uk Accessed April 20, 2013
   Google Scholar
• Bear CE Li CH Kartner N Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR) Cell 1992 68 809 818 1371239
   PubMed Web of Science ®Google Scholar
• Gadsby DC Vergani P Csanady L The ABC protein turned chloride channel whose failure causes cystic fibrosis Nature 2006 440 477 483 16554808
   PubMed Web of Science ®Google Scholar
• Knowles M Gatzy J Boucher R Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis N Engl J Med 1981 305 1489 1495 7300874
   PubMed Web of Science ®Google Scholar
• Mall M Grubb BR Harkema JR O’Neal WK Boucher RC Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice Nat Med 2004 10 487 493 15077107
   PubMed Web of Science ®Google Scholar
• Farrell PM Rosenstein BJ White TB Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report J Pediatr 2008 153 S4 S14 18639722
   PubMed Web of Science ®Google Scholar
• Kerem B Chiba-Falek O Kerem E Cystic fibrosis in Jews: frequency and mutation distribution Genet Test 1997 1 35 39 10464623
   PubMedGoogle Scholar
• McKone EF Emerson SS Edwards KL Aitken ML Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study Lancet 2003 361 1671 1676 12767731
   PubMed Web of Science ®Google Scholar
• Hamosh A King TM Rosenstein BJ Cystic fibrosis patients bearing both the common missense mutation Gly-Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus Am J Hum Genet 1992 51 245 250 1379413
   PubMed Web of Science ®Google Scholar
• Highsmith WE Burch LH Zhou Z A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations N Engl J Med 1994 331 974 980 7521937
   PubMed Web of Science ®Google Scholar
• Kulczycki LL Kostuch M Bellanti JA A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype-phenotype manifestations Am J Med Genet A 2003 116A 262 267 12503104
   PubMed Web of Science ®Google Scholar
• Davis PB Schluchter MD Konstan MW Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis Pediatr Pulmonol 2004 38 204 209 15274098
   PubMed Web of Science ®Google Scholar
• McKone EF Goss CH Aitken ML CFTR genotype as a predictor of prognosis in cystic fibrosis Chest 2006 130 1441 1447 17099022
   PubMed Web of Science ®Google Scholar
• de Gracia J Mata F Alvarez A Genotype-phenotype correlation for pulmonary function in cystic fibrosis Thorax 2005 60 558 563 15994263
   PubMed Web of Science ®Google Scholar
• Shoshani T Augarten A Gazit E Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease Am J Hum Genet 1992 50 222 228 1370365
   PubMed Web of Science ®Google Scholar
• Rowntree RK Harris A The phenotypic consequences of CFTR mutations Ann Hum Genet 2003 67 471 485 12940920
   PubMed Web of Science ®Google Scholar
• Van Goor F Straley KS Cao D Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules Am J Physiol Lung Cell Mol Physiol 2006 290 L1117 L1130 16443646
   PubMed Web of Science ®Google Scholar
• Clinical and Functional Translation of CFTR CFTR2 Available from: http://www.cftr2.com Accessed January 19, 2013
   Google Scholar
• Oakland M Sinn PL McCray PBJr Advances in cell and gene-based therapies for cystic fibrosis lung disease Mol Ther 2012 20 1108 1115 22371844
   PubMed Web of Science ®Google Scholar
• The UK Cystic Fibrosis Gene Therapy Consortium Gene therapy multi-dose clinical trial Available from: http://www.cfgenetherapy.org.uk Accessed April 20, 2013
   Google Scholar
• Carlile GW Robert R Zhang D Correctors of protein trafficking defects identified by a novel high-throughput screening assay Chembiochem 2007 8 1012 1020 17497613
   PubMed Web of Science ®Google Scholar
• Galietta LV Jayaraman S Verkman AS Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists Am J Physiol Cell Physiol 2001 281 C1734 C1742 11600438
   PubMed Web of Science ®Google Scholar
• Van Goor F Hadida S Grootenhuis PD Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 Proc Natl Acad Sci U S A 2009 106 18825 18830 19846789
   PubMed Web of Science ®Google Scholar
• Eckford PD Li C Ramjeesingh M Bear CE Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner J Biol Chem 2012 287 36639 36649 22942289
   PubMed Web of Science ®Google Scholar
• Ramsey BW Davies J McElvaney NG A CFTR potentiator in patients with cystic fibrosis and the G551D mutation N Engl J Med 2011 365 1663 1672 22047557
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals Kalydeco© Available from: http://www.ema.europa.eu/docs/en_GB/document_library Acessed January 20, 2013
   Google Scholar
• [No authors listed] Ivacaftor (Kalydeco) for cystic fibrosis Med Lett Drugs Ther 2012 54 29 30 22499233
   PubMed Web of Science ®Google Scholar
• De Boeck K Kent L Davies J CFTR biomarkers: time for promotion to surrogate end-point Eur Respir J 2013 41 203 216 22878883
   PubMed Web of Science ®Google Scholar
• Konstan MW Wagener JS Yegin A Millar SJ Pasta DJ Vandevanter DR Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint J Cyst Fibros 2010 9 332 338 20646968
   PubMed Web of Science ®Google Scholar
• Que C Cullinan P Geddes D Improving rate of decline of FEV1 in young adults with cystic fibrosis Thorax 2006 61 155 157 16384880
   PubMed Web of Science ®Google Scholar
• Durmowicz AG Witzmann KA Rosebraugh CJ Chowdhury BA Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience Chest 2013 143 14 18 23276841
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Notification to the Cystic Fibrosis Community on Kalydeco (ivacaftor) Available from: http://www.fda.gov/Drugs/DrugSafety Accessed April 20, 2013
   Google Scholar
• Bush A Simmonds NJ Hot off the breath: ‘I’ve a cost for’ – the 64 million dollar question Thorax 2012 67 382 384 22407889
   PubMed Web of Science ®Google Scholar
• Fuchs HJ Borowitz DS Christiansen DH Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group N Engl J Med 1994 331 637 642 7503821
   PubMed Web of Science ®Google Scholar
• Equi A Balfour-Lynn IM Bush A Rosenthal M Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial Lancet 2002 360 978 984 12383667
   PubMed Web of Science ®Google Scholar
• Yu H Burton B Huang CJ Ivacaftor potentiation of multiple CFTR channels with gating mutations J Cyst Fibros 2012 11 237 245 22293084
   PubMed Web of Science ®Google Scholar
• Davis PB Yasothan U Kirkpatrick P Ivacaftor Nat Rev Drug Discov 2012 11 349 350 22543461
   PubMed Web of Science ®Google Scholar
• Flume PA Liou TG Borowitz DS Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation Chest 2012 142 718 724 22383668
   PubMed Web of Science ®Google Scholar
• Van Goor F Hadida S Grootenhuis PD Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Proc Natl Acad Sci U S A 2011 108 18843 18848 21976485
   PubMed Web of Science ®Google Scholar
• Zhang L Button B Gabriel SE CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium PLoS Biol 2009 7 e1000155 19621064
   PubMed Web of Science ®Google Scholar
• Clancy JP Rowe SM Accurso FJ Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation Thorax 2012 67 12 18 21825083
   PubMed Web of Science ®Google Scholar
• Boyle M The investigational CFTR corrector, VX-809, co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508del homozygous patients: Phase 2 study results Poster 260 presented at the 26th North American Cystic Fibrosis Conference Orlando, FL October 11–13, 2012
   Google Scholar
• ClinicalTrials.gov Study of VX-661 alone and in combination with VX-770 in subjects homozygous to the F508del-CFTR mutation Available from: http://clinicaltrials.gov/show/NCT01531673 Accessed April 20, 2013
   Google Scholar
• Vertex Treatment with VX-661 and ivacaftor in a Phase 2 study resulted in statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation Available from: http://investors.vrtx.com/releasedetail.cfm?releaseid=757597 Accessed April 20, 2013
   Google Scholar
• Welch EM Barton ER Zhuo J PTC124 targets genetic disorders caused by nonsense mutations Nature 2007 447 87 91 17450125
   PubMed Web of Science ®Google Scholar
• Kerem E Hirawat S Armoni S Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial Lancet 2008 372 719 727 18722008
   PubMed Web of Science ®Google Scholar
• Clancy JP Rowe SM Bebok Z No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations Am J Respir Cell Mol Biol 2007 37 57 66 17347447
   PubMed Web of Science ®Google Scholar
• Kerem E Wilschanski M De Boeck K Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data J Cyst Fibros 2011 10 S17
   Google Scholar
• PTC Therapeutics Inc Top-line data from phase 3 trial of ataluren in patients with nonsense mutation cystic fibrosis show promising results Available from: http://ptct.Client.Shareholder.Com/releasedetail Accessed January 26, 2013
   Google Scholar
• Mendell JR Rodino-Klapac L Sahenk Z Gene therapy for muscular dystrophy: lessons learned and path forward Neurosci Lett 2012 527 90 99 22609847
   PubMed Web of Science ®Google Scholar
• Hyde SC Painter H Gill DR EnaC knockdown in the mouse lung using RNAI Pediatr Pulmonol 2007 42 306
   Google Scholar
• Harding-Smith RE Gill DR Hyde SC Knockdown of ENaCá, as a treatment for cystic fibrosis lung disease Mol Ther 2011 19 1360 1398
   Web of Science ®Google Scholar
• Wang X Venable J LaPointe P Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis Cell 2006 127 803 815 17110338
   PubMed Web of Science ®Google Scholar
• Hutt DM Herman D Rodrigues AP Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis Nat Chem Biol 2010 6 25 33 19966789
   PubMed Web of Science ®Google Scholar